Population Pharmacokinetics of Radotinib in Healthy Volunteers and Patients with Chronic Myeloid Leukemia
<b>Background/Objectives</b>: Radotinib is a second-generation tyrosine kinase inhibitor (TKI) that has been used for treatment of chronic myeloid leukemia (CML). This study was performed for the first time to characterize the pharmacokinetics of radotinib, identify the factors contributing to pharm...
Na minha lista:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI AG
2025-11-01
|
| Colecção: | Pharmaceuticals |
| Assuntos: | |
| Acesso em linha: | https://www.mdpi.com/1424-8247/18/11/1705 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|